Startups
QurAlis
Cambridge, Massachusetts, United States
QurAlis Corporation is a Cambridge, Massachusetts biotechnology company developing precision medicines for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and other neurodegenerative diseases. Its research combines disease genetics, patient-derived stem-cell models and biomarkers with small-molecule and antisense oligonucleotide therapies. Its FlexASO platform develops splice-modulating antisense compounds; clinical programmes include QRL-201 and QRL-101. The company is relevant to neuroscience and advanced biotechnology; no unsupported artificial-intelligence claim is made. The current own team page, modified September9,2026, publishes seven executives, nine board members, eight scientific advisers and five clinical advisers, representing28 distinct people. Kasper Roet serves as CEO and board member; Kevin Eggan and Clifford Woolf also have explicit founder affiliations. An obsolete hidden Jinsy Andrews modal is not treated as current roster membership. Manoj Malhotra is the current CMO, superseding older Doug Williamson announcements. One published adviser modal incorrectly reuses Manoj’s photo; Ammar Al-Chalabi’s authentic original portrait is instead verified against his own King’s College London biography. Shared people’s biographies, portraits and external affiliations are preserved. Primary financing includes an undisclosed-size seed round reported April5,2018, USD42million SeriesA announced May13,2020, and USD88million SeriesB closed March9,2023. Cumulative totals are not additional rounds. A June3,2024 Lilly agreement combines an upfront USD45million licensing payment with a separately stated equity investment of undisclosed amount; the licensing payment and potential USD577million future milestones are not equity fundraising. ALS Association research awards are recorded separately from private investment. The2017 Amgen Golden Ticket provided laboratory space and services, not an inferred cash financing. SEC filings identify the Delaware corporation, incorporated in2016 (CIK1811817). Separate convertible-promissory-note offerings reported USD5million securities sold in2022 and USD19,952,387 in2025; their targets of USD10million and USD24,921,734 are not completed raises. The cash fields remain unquantified pending reconciliation of note conversions with later equity financing. SeriesA andB SEC snapshots describe those same offerings and are not extra rounds. The March2026 corporate presentation explicitly described SeriesC funding as pending.
Team
 Ammar Al-ChalabiClinical Advisory Board Member |
 Amy SchulmanBoard Member |
 Anne C. WhitakerChair of the Board |
 Bernhardt L. TroutScientific Advisory Board Member |
 Brian J. WaingerScientific Advisory Board Member |
 Christopher Shaw (Neurology)Scientific Advisory Board Member |
 Cillian KingBoard Member |
 Clifford WoolfScientific Advisory Board Member · Co-Founder |
 Dame Pamela J. ShawClinical Advisory Board Member |
 Dan ElbaumChief Scientific Officer |
 Guzide AdhikariSenior Vice President, CMC Operations & Strategy |
 Hagen CramerChief Technology Officer |
 Jason BrownChief Financial Officer and Chief Operating Officer |
 Johannes FruehaufBoard Member |
 John SimsBoard Member |
 Kasper RoetFounder, Chief Executive Officer · Board Member |
 Kevin EgganScientific Advisory Board Member · Co-Founder |
 Laia CrespoBoard Member |
 Leonard van den BergClinical Advisory Board Member |
 Luc DochezBoard Member |
 Manoj MalhotraChief Medical Officer |
 Matthew KiernanScientific Advisory Board Member |
 Merit CudkowiczClinical Advisory Board Member |
 Michelle L. HastingsScientific Advisory Board Member |
 Philip Van DammeClinical Advisory Board Member |
 Shafique ViraniBoard Member |
 Sudhir AgrawalScientific Advisory Board Member |
 Vikas SharmaChief Business Officer |